The document discusses Critical Outcome Technologies Inc. (COTI), a bioinformatics company that uses its proprietary CHEMSAS platform to accelerate drug discovery and reduce costs. The CHEMSAS platform uses artificial intelligence and computational modeling to simulate the drug discovery process in silico, identifying promising compounds faster and cheaper than traditional wet-lab approaches. COTI has multiple collaborations utilizing the platform and an oncology drug candidate, COTI-2, that shows promise for cancers with p53 mutations and is nearing phase 1 clinical trials. The platform also positions COTI for numerous potential licensing deals and revenue streams from drug development milestones and royalties.

1. The future of drug discovery has arrived
TSX-V: COT | January 2014

2. Disclaimer
When used anywhere in this presentation, whether oral or written, the words
expects, believes, anticipates, estimates and similar expressions are intended to identify
forward-looking statements. Forward-looking statements may include statements
addressing future financial and operating results of Critical Outcome Technologies Inc.
(COTI).
COTI bases these forward-looking statements on its current expectations about future
events. Such statements are subject to risks and uncertainties including, but not limited
to, the successful implementation of COTI’s strategic plans, the acceptance of new
products, the obsolescence of existing products, the resolution of potential patent
issues, competition, changes in economic conditions, and other risks described in COTI’s
public documents such as press releases and filings with the Toronto Stock Exchange and
the Ontario Securities Commission.
All forward-looking statements are qualified in their entirety by the cautionary statements
included in this document and such filings. These risks and uncertainties could cause
actual results to differ materially from results expressed or implied by forward-looking
statements contained in this presentation. These forward-looking statements speak only
as of the date of this presentation.
2

3. Who we are
• A bioinformatics
and accelerated
drug discovery
company
• Established in 2005
• Listed on the TSX-V
under the symbol COT
3

4. Investment highlights
1
We reduce the time, cost & risk of
bringing new drugs to market
2
Scalable platform technology enables
multiple concurrent projects
3
Potential cancer breakthrough is (nearly)
Phase 1 ready
4

5. What we do
• Reduce drug discovery, optimization & lead
selection by 1.5 to 3 yrs.
• Saving significant $$$
• Increasing revenue period under patent
protection
5

6. How we do it
CHEMSAS®
• Proprietary platform
technology
• Artificial intelligence
+ proprietary
algorithms
+ medicinal
chemistry expertise
6

7. Advantages of CHEMSAS®
• Computational replication of traditional ‘wet lab’
drug discovery process
• Failed attempts occur quickly & cheaply in
computer simulations, not the ‘research bench’
• Higher probability of clinical & commercial
success
7

8. Scalable platform technology
• Enables multiple concurrent revenue
opportunities
• 3 existing R&D collaborations
- Western University
- Delmar Chemicals
- Major Pharma Co.
• Collaborations expected to bring in multiple
milestone payments beginning late 2014 /
2015
8

9. Scalable platform technology
• Robust internal pipeline of compounds
– COTI-2, AML, etc.
• Strategy to license our own compounds
– Upfront payments, milestones, royalties
9

10. Potential
cancer
breakthrough
Our lead
compound, COTI2, is effective against
cancers with
mutations of the p53
gene
10

11. > 50% of all human cancers
have a p53 mutation
(eg. ~95% of ovarian cancers)
Why COTI-2
is exciting
Mechanism of action
confirmed by thought leader
Dr. Gordon Mills at MD
Anderson Cancer Center
(June 2013)
Novel, first in class
Strong IP protection in place
11

12. COTI-2 is (nearly) Phase 1 ready
• In final 2-species toxicity studies – completion in
first half of 2014
• FDA filing expected mid-to-late 2014 (leading to
Phase 1 clinical trial)
• Pursuing orphan drug &/or breakthrough therapy
status
• Seeking optimal partner for clinical development
12

13. COTI-2 = significant revenue potential
• Top 5 2012 Phase 1/2 oncology licensing deals
disclosed (1):
• Upfront payments of approx. $25-$92 million
• Milestone payments between $550-$1,100 million
• Royalties on net sales
• 1st half of 2013 (2) – 16 phase 1 licensing deals
with 6 in cancer – avg. upfront $30m
(1)
(2)
Medius Associates
Thomson Reuters
13

14. Looking ahead:
Project ROSALIND
• Programmable computer simulation of human
cancer cell signaling
• Better personalized treatment decisions based on
genetic profile of one’s cancer
• Personalized cancer gene profiling projected to be
*
~$35B market by 2018
*
Markets and Markets (2013)
14

15. The future of drug discovery has arrived
Dr. Wayne Danter
President & CEO
Tel: (519) 858-5157
wdanter@criticaloutcome.com
www.criticaloutcome.com
www.facebook.com/criticaloutcome
twitter.com/criticaloutcome
www.slideshare.net/criticaloutcome